OnCo

Gastrointestinal stromal tumour (GIST): lines of therapy

Cancer page →

4 standard-of-care settings across 4 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised1
Advanced, first line1
Second line1
Third line and beyond1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersLocalised, resectableComplete resection without lymphadenectomy; adjuvant imatinib 3 years for high-risk (SSGXVIII); neoadjuvant imatinib to downsize when organ-sparing matters.78

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced, first lineImatinib 400 mg (800 mg for KIT exon 9); avapritinib for PDGFRA D842V; continue until progression.78

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced, second lineSunitinib (or ripretinib for KIT exon 11 + 17/18 secondary mutations per ctDNA, INSIGHT).94

Third line and beyond

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced, third/fourth lineRegorafenib, then ripretinib (INVICTUS); rechallenge or continue TKI beyond progression; clinical trials (bezuclastinib-sunitinib).93

Regimens in the library

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.